(NASDAQ:DNTH), NEW YORK and WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in the 44th Annual J.P. Morgan Healthcare conference in San Francisco. Marino Garcia, CEO of Dianthus […]

(NasdaqGM:SION), WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) — Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at

(NASDAQ:SNDX), NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 3:00 p.m. PT/ 6:00 p.m. ET. A live webcast

CHARLESTON, SC, Jan. 05, 2026 (GLOBE NEWSWIRE) — Sonepar, the world's leading B2B distributor of electrical equipment, solutions, and services, is proud to announce the launch of its first national customer appreciation initiative for electrical contractors. January Jumpstart will run throughout the month of January across 12 Sonepar brands in the U.S. This exclusive sales

Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors GlobeNewswire January 05, 2026 CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track to

Mobilicom Announces New Design Win and Initial Order from United Arab Emirates-Based Arms Manufacturer GlobeNewswire January 05, 2026 New customer engagement supports Mobilicom's expansion across the Middle East region, with live prototype demonstration planned at UMEX Abu Dhabi in January 2026 Palo Alto, California, Jan. 05, 2026 (GLOBE NEWSWIRE) — Mobilicom Limited (Nasdaq: MOB, MOBBW)

OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer GlobeNewswire January 05, 2026 Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on the Board LONDON and NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) —

GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026 GlobeNewswire January 05, 2026 GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment Company to seek FDA alignment on global Phase 3 program replicating Phase 2b design Phase 3 initiation targeted for 2026 DUBLIN,

Mobix Labs Powers Up U.S. Defense Operations: Veteran Defense GM Takes the Helm; Bigger Military-Approved Facility Expansion Planned GlobeNewswire January 05, 2026 ~ Larger military-approved facility expansion planned to increase defense- manufacturing ~ ~ Veteran defense GM appointed to lead execution as Mobix Labs Plans facility expansion ~ IRVINE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE)

Beamr 2026 Strategy and 2025 Highlights GlobeNewswire January 05, 2026 Beamr CEO, Sharon Carmel, presents the Company milestones and strategy Herzliya, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) — Beamr Imaging Ltd. (NASDAQ: BMR), a leader in video optimization technology and solutions, today issued a Letter to Shareholders from Sharon Carmel, Chief Executive Officer. Dear Shareholders: